{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:14:14Z","timestamp":1791778454531,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,1,10]],"date-time":"2006-01-10T00:00:00Z","timestamp":1136851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1007\/s00432-005-0074-4","type":"journal-article","created":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T16:46:28Z","timestamp":1136825188000},"page":"205-212","source":"Crossref","is-referenced-by-count":166,"title":["Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone\u2014a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)"],"prefix":"10.1007","volume":"132","author":[{"given":"W.","family":"P\u00f6nisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Mitrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dachselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"\u0160ubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Harksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Grobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pasold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th.","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,10]]},"reference":[{"issue":"6","key":"74_CR1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cpt1979266737","volume":"26","author":"DS Alberts","year":"1979","unstructured":"Alberts DS, Chang SY, Chen HS, Evans TL, Moon TE (1979) Oral melphalan kinetics. Clin Pharmacol Ther 26(6):737\u2013745","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"74_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","volume":"330","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330(7):484\u2013489","journal-title":"N Engl J Med"},{"issue":"2","key":"74_CR3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C","volume":"30","author":"R Alexanian","year":"1972","unstructured":"Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M et al (1972) Combination chemotherapy for multiple myeloma. Cancer 30(2):382\u2013389","journal-title":"Cancer"},{"issue":"48","key":"74_CR4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1055\/s-0028-1110470","volume":"94","author":"G Anger","year":"1969","unstructured":"Anger G, Hesse P, Baufeld H (1969) Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride. DMW 94(48):2495\u20132500","journal-title":"DMW"},{"issue":"27","key":"74_CR5","first-page":"1280","volume":"30","author":"G Anger","year":"1975","unstructured":"Anger G, Fink R, Fleischer J, Hesse P, Krug K, Raderecht C et al (1975) Vergleichsuntersuchungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom. Dt Gesundh -Wesen 30(27):1280\u20131285","journal-title":"Dt Gesundh -Wesen"},{"issue":"2","key":"74_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"G Attal","year":"1996","unstructured":"Attal G, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 335(2):91\u201397","journal-title":"New Engl J Med"},{"issue":"1","key":"74_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93(1):55\u201365","journal-title":"Blood"},{"issue":"1","key":"74_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0889-8588(05)70420-2","volume":"11","author":"WI Bensinger","year":"1997","unstructured":"Bensinger WI, Buckner D, Gahrton G (1997) Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 11(1):147\u2013157","journal-title":"Hematol Oncol Clin North Am"},{"issue":"87","key":"74_CR9","first-page":"99","volume":"21","author":"DE Bergsagel","year":"1962","unstructured":"Bergsagel DE, Sprague CC, Austin C, Griffith KM (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 21(87):99","journal-title":"Cancer Chemother Rep"},{"issue":"14","key":"74_CR10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","volume":"301","author":"DE Bergsagel","year":"1979","unstructured":"Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB (1979) The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301(14):743\u2013748","journal-title":"N Engl J Med"},{"issue":"5","key":"74_CR11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematology 102(5):1115\u20131123","journal-title":"Br J Haematology"},{"key":"74_CR12","first-page":"68","volume":"124","author":"K Blumenstengel","year":"1998","unstructured":"Blumenstengel K, Ruffert K, Frincke HJ, Kath R, H\u00f6ffken K (1998) Bendamustine vs. Melphalan in the primary treatment of multiple myeloma (MM). A randomized prospective study. J Cancer Res Clin Oncol 124:68","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"74_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0277-5379(82)90006-2","volume":"18","author":"AG Bosanquet","year":"1982","unstructured":"Bosanquet AG, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18(4):355\u2013362","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"74_CR14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842\u2013854","journal-title":"Cancer"},{"issue":"2","key":"74_CR15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF02985238","volume":"6","author":"H Ehrsson","year":"1989","unstructured":"Ehrsson H, Eksborg S, Osterborg A, Mellstedt H, Lindfors A (1989) Oral melphalan pharmacokinetics\u2013relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 6(2):151\u2013154","journal-title":"Med Oncol Tumor Pharmacother"},{"issue":"3","key":"74_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0277-5379(90)90240-T","volume":"26","author":"JO Fernberg","year":"1990","unstructured":"Fernberg JO, Johansson B, Lewensohn R, Mellstedt H (1990) Oral dosage of melphalan and response to treatment in multiple myeloma. Eur J Cancer 26(3):393\u2013396","journal-title":"Eur J Cancer"},{"issue":"1","key":"74_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","volume":"113","author":"G Gahrton","year":"2001","unstructured":"Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Bjorkstrand B et al (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u20131993 and 1994\u20131998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113(1):209\u2013216","journal-title":"Br J Haematol"},{"issue":"1","key":"74_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics 2001. CA Cancer J Clin 51(1):15\u201336","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"74_CR19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","volume":"10","author":"WM Gregory","year":"1992","unstructured":"Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10(2):334\u2013342","journal-title":"J Clin Oncol"},{"issue":"11","key":"74_CR20","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","volume":"85","author":"J-L Harousseau","year":"1995","unstructured":"Harousseau J-L, Attal M, Divine M, Marit G, Leblond V, Stoppa A-M et al (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 85(11):3077\u20133085","journal-title":"Blood"},{"issue":"11","key":"74_CR21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","volume":"124","author":"K Hoeffken","year":"1998","unstructured":"Hoeffken K, Merkle K, Schoenfelder M, Anger G, Brandtner M, Ridwelski K et al (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124(11):627\u2013632","journal-title":"J Cancer Res Clin Oncol"},{"key":"74_CR22","first-page":"29","volume":"50","author":"RA Kyle","year":"1975","unstructured":"Kyle RA (1975) Multiple myeloma: review of 869 cases. Mayo Clin Proc 50:29\u201340","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"74_CR23","first-page":"640a","volume":"102","author":"LM Leoni","year":"2003","unstructured":"Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L et al (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood 102(11):640a","journal-title":"Blood"},{"issue":"12","key":"74_CR24","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16(12):3832\u20133842","journal-title":"J Clin Oncol"},{"issue":"8","key":"74_CR25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0025-6196(12)61100-8","volume":"69","author":"MM Oken","year":"1994","unstructured":"Oken MM (1994) Standard treatment of multiple myeloma. Mayo Clin Proc 69(8):781\u2013786","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"74_CR26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0959-8049(05)80205-9","volume":"29A","author":"D Peest","year":"1993","unstructured":"Peest D, Coldewey R, Deicher H, Sailer M, Vykoupil C, Leo R et al (1993) Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups. Eur J Cancer 29A(7):978\u2013983","journal-title":"Eur J Cancer"},{"issue":"2","key":"74_CR27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","volume":"31A","author":"D Peest","year":"1995","unstructured":"Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H et al (1995) A comparison of polychemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A(2):146\u2013151","journal-title":"Eur J Cancer"},{"issue":"3","key":"74_CR28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.V91.3.1029","volume":"91","author":"HGP Raaijmakers","year":"1998","unstructured":"Raaijmakers HGP, Izquierdo MAI, Lokhorst HM, de Leeuw C, Belien JAM, Bloem AC et al (1998) Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 91(3):1029\u20131036","journal-title":"Blood"},{"issue":"1","key":"74_CR29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11864-000-0017-x","volume":"1","author":"N Raje","year":"2000","unstructured":"Raje N, Anderson KC (2000) Multiple myeloma. Curr Treat Options Oncol 1(1):73\u201382","journal-title":"Curr Treat Options Oncol"},{"issue":"26","key":"74_CR30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PC Richardson","year":"2003","unstructured":"Richardson PC, Barlogie B, Berenson J, Sighal S, Jagannath S, Irwin D et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609\u20132617","journal-title":"N Engl J Med"},{"issue":"4","key":"74_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4):415\u2013421","journal-title":"Anticancer Drugs"},{"issue":"3","key":"74_CR32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V88.3.838.838","volume":"88","author":"DH Vesole","year":"1996","unstructured":"Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D et al (1996) Autotransplants in multiple myeloma: what have we learned? Blood 88(3):838\u2013847","journal-title":"Blood"},{"issue":"3","key":"74_CR33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11864-002-0013-4","volume":"3","author":"DM Weber","year":"2002","unstructured":"Weber DM (2002) Newly diagnosed multiple myeloma. Curr Treat Options Oncol 3(3):235\u2013245","journal-title":"Curr Treat Options Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-005-0074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0074-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T04:01:14Z","timestamp":1683345674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-005-0074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s00432-005-0074-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,10]]}}}